[{"address1": "100 Campus Drive", "city": "Florham Park", "state": "NJ", "zip": "07932", "country": "United States", "phone": "608 441 8120", "website": "https://www.cellectar.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.", "fullTimeEmployees": 20, "companyOfficers": [{"maxAge": 1, "name": "Mr. James V. Caruso", "age": 64, "title": "President, CEO & Director", "yearBorn": 1959, "fiscalYear": 2023, "totalPay": 1142418, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jarrod  Longcor", "age": 50, "title": "Chief Operating Officer", "yearBorn": 1973, "fiscalYear": 2023, "totalPay": 854242, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Darrell Shane Lea", "age": 49, "title": "Chief Commercial Officer", "yearBorn": 1974, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Andrei  Shustov M.D.", "age": 51, "title": "Senior Vice President of Medical", "yearBorn": 1972, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 3.1, "open": 3.1, "dayLow": 3.045, "dayHigh": 3.14, "regularMarketPreviousClose": 3.1, "regularMarketOpen": 3.1, "regularMarketDayLow": 3.045, "regularMarketDayHigh": 3.14, "beta": 0.936, "forwardPE": -1.0918728, "volume": 533868, "regularMarketVolume": 533868, "averageVolume": 1012383, "averageVolume10days": 873420, "averageDailyVolume10Day": 873420, "bid": 3.08, "ask": 3.11, "bidSize": 600, "askSize": 2300, "marketCap": 99684944, "fiftyTwoWeekLow": 1.33, "fiftyTwoWeekHigh": 4.45, "fiftyDayAverage": 3.602, "twoHundredDayAverage": 2.793, "currency": "USD", "enterpriseValue": 96732624, "floatShares": 24211835, "sharesOutstanding": 32260500, "sharesShort": 2194327, "sharesShortPriorMonth": 1884424, "sharesShortPreviousMonthDate": 1710460800, "dateShortInterest": 1713139200, "sharesPercentSharesOut": 0.068, "heldPercentInsiders": 0.03558, "heldPercentInstitutions": 0.26396, "shortRatio": 1.96, "shortPercentOfFloat": 0.0681, "impliedSharesOutstanding": 32687800, "bookValue": -0.357, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -37983496, "trailingEps": -3.11, "forwardEps": -2.83, "lastSplitFactor": "1:10", "lastSplitDate": 1658448000, "enterpriseToEbitda": -2.495, "52WeekChange": 1.0463576, "SandP52WeekChange": 0.23099434, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "CLRB", "underlyingSymbol": "CLRB", "shortName": "Cellectar Biosciences, Inc.", "longName": "Cellectar Biosciences, Inc.", "firstTradeDateEpochUtc": 1131633000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "d92a6d57-8c29-3e38-89dc-584b57cac7f0", "messageBoardId": "finmb_37613299", "gmtOffSetMilliseconds": -14400000, "currentPrice": 3.09, "targetHighPrice": 25.0, "targetLowPrice": 4.0, "targetMeanPrice": 12.6, "targetMedianPrice": 12.0, "recommendationMean": 1.6, "recommendationKey": "buy", "numberOfAnalystOpinions": 5, "totalCash": 9564988, "totalCashPerShare": 0.296, "ebitda": -38768268, "totalDebt": 552982, "quickRatio": 0.739, "currentRatio": 0.808, "returnOnAssets": -1.44661, "returnOnEquity": -5.3681297, "freeCashflow": -15436557, "operatingCashflow": -32376974, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-05-01"}]